Docetaxel plus cisplatin in non-small-cell lung cancer
- PDF / 83,166 Bytes
- 3 Pages / 667 x 914 pts Page_size
- 29 Downloads / 256 Views
Docetaxel plus cisplatin in non-small-cell lung cancer Adapted and reproduced from Am J Cancer 2003; 2 (5): 349-358[1-4] Lung cancer is now the leading cause of cancer death in both men and women in the US.[1] Lung cancer can be classified as small cell or non-small-cell lung cancer (NSCLC) according to histology; most newly diagnosed cases fit into the latter category (≈80%).[5] When diagnosed, the majority of patients with NSCLC have advanced, often inoperable disease.[5] Docetaxel (Taxotere®)1 and cisplatin (Platinol®) are well established antineoplastic agents with activity against NSCLC.[6,7] The combination exhibited additive cytotoxic activity against human NSCLC cell lines in vitro.[8] In a large phase III trial in chemotherapy-naive patients with advanced NSCLC,[9] survival with docetaxel plus cisplatin was statistically noninferior to that with the control regimen of vinorelbine plus cisplatin. Overall response rate with docetaxel plus cisplatin was significantly higher than with the control. Median survival times, tumour response rates, and median time to progression for patients receiving docetaxel plus cisplatin were similar to those for patients receiving paclitaxel plus cisplatin in another large phase III trial.[10] Neutropenia was the most common grade 3/4 adverse event in docetaxel/cisplatin recipients (≥69% of patients in the two large phase III trials); these proportions were not significantly different from those for patients receiving controls.[9,10] Grade 3/4 vomiting, nausea, or anaemia were significantly less common than with vinorelbine plus cisplatin,[9] whereas hypersensitivity reactions were significantly more common than with paclitaxel plus cisplatin.[10]
Docetaxel plus cisplatin A Viewpoint by Chandra Belani and Sakkaraiappan Ramalingam[2] University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA The treatment of advanced NSCLC has evolved over the past few years. Platinum-based two-drug combination chemotherapy, considered as the ‘standard of care’, results in modest improvements in both survival and quality of life. The use of the docetaxel/cisplatin combination for the treatment of chemotherapy-naive 1 The use of tradenames is for product identification purposes only and does not imply endorsement.
patients with advanced NSCLC has been evaluated in randomised clinical trials. The TAX 326 Study led to the FDA approval of this combination for the treatment of chemotherapy-naive patients with advanced/metastatic disease. It demonstrated higher median survival (11.3 vs 10.1 months, p = 0.044) and response rates (32% vs 25%, p = 0.029) for the docetaxel/cisplatin arm compared with the control arm of vinorelbine/cisplatin. Consistent improvements in several quality-of-life parameters were noted for patients in the two docetaxel arms compared with the control arm. Thus, both docetaxel/cisplatin and docetaxel/carboplatin now
Features and properties of docetaxel (Taxotere®) plus cisplatin (Platinol®)[1] Indications Advanced non-small-cel
Data Loading...
